Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Swiss approve ceftobiprole

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Swissmedic approves Basilea/Johnson & Johnson's ceftobiprole Nov. 13 to treat complicated skin and soft tissue infections, including diabetic foot infections. Already marketed in Canada as Zeftera, the novel broad-spectrum anti-MRSA cephalosporin antibiotic will be marketed in Switzerland as Zevtera. FDA recently accepted Basilea/J&J's response to an "approvable" letter for the compound in the U.S. for the same indication, giving the NDA a Class 2 designation, which means a six-month review (1Pharmaceutical Approvals Monthly May 2008, p. 6). On Nov. 18-20, FDA's Anti-Infective Drugs Advisory Committee is scheduled to discuss non-inferiority margins for CSSI studies and NDAs for possible competitors in the space, Theravance's telavancin and Arpida AG's iclaprim

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts